For high throughput crystallography companies, the business model of choice is up for grabs. However, for MediChem Life Sciences Inc., the strategy is quite clear - and it does not involve selling a comprehensive database of protein structures.

The company believes the best way to capture value in this business is through a three-pronged approach involving contract services, sales of crystallography-related reagents and instrumentation, and internal drug development projects.